Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 23 recruiting now early-phase tilt

Cognitive Dysfunction: early-phase trial registry

23 of 46 indexed Cognitive Dysfunction trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #312 of 28,707 conditions by registered trial count.

46 US clinical trials · 23 currently recruiting · #312 of 28,707 conditions by registered trial count

Cognitive Dysfunction: 46 US clinical trials tracked, 23 recruiting.

Cognitive Dysfunction is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 23 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Dartmouth-Hitchcock Medical Center, running 5 of these trials.

Enrollment posture brief

Registry condition cognitive-dysfunction

OPEN 23 | RECR 50% | LATE 1 | EARLY 8 | RANK #312 | SPON 5

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Cognitive Dysfunction (this)50%Hematologic Malignancies47.8%Endothelial Dysfunction45.7%Cigarette Smoking43.5%Clear Cell Renal Cell Carcin30.4%
Open-enrollment share among volume-matched conditions near Cognitive Dysfunction

Cognitive Dysfunction lists 23 open slots (50% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cognitive Dysfunction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cognitive Dysfunction is recruiting above its size-band peers.

    23 of 46 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cognitive Dysfunction trials is spread across many organizations.

    Dartmouth-Hitchcock Medical Center accounts for 5 of 46 trials (10.9%). 34 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cognitive Dysfunction enrolment sits around 75 participants.

    Median target enrolment is 75 among the 46 trials that report a genuine target (sentinel values excluded). 25 of those (54.3%) plan for fewer than 100 participants.

  4. Cognitive Dysfunction research is mostly interventional.

    34 interventional and 12 observational studies make up this index (73.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 25Phase 31

Open and recent trials

46 total, page 1 of 1

RECRUITING 25,240 participants

PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing

University of Florida

NCT03175302

RECRUITING NA 1,800 participants

Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers

University of Washington

NCT05596760

RECRUITING 1,000 participants

Vanderbilt Memory and Aging Project

Vanderbilt University Medical Center

NCT05372159

RECRUITING 1,000 participants

Tennessee Alzheimer's Project

Vanderbilt University Medical Center

NCT05372172

RECRUITING NA 300 participants

Polyphenols and Cognitive Decline

University of California, Los Angeles

NCT06507254

RECRUITING Phase 2 144 participants

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

University of Virginia

NCT05565833

RECRUITING NA 125 participants

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

Dartmouth-Hitchcock Medical Center

NCT06930846

RECRUITING NA 125 participants

HOBSCOTCH-MS-Efficacy Trial

Dartmouth-Hitchcock Medical Center

NCT06951919

RECRUITING NA 120 participants

Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults

University of Florida

NCT05830942

RECRUITING NA 120 participants

Strengthening Neuro-Cognitive Skills for Success in School, Work and Beyond

VA Office of Research and Development

NCT04109027

RECRUITING NA 75 participants

Cognitive Remediation

Cutter Lindbergh

NCT07171450

RECRUITING NA 70 participants

Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment

University of California, Los Angeles

NCT04558164

RECRUITING NA 60 participants

High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV

University of Alabama at Birmingham

NCT05965518

RECRUITING 60 participants

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

Joseph McCollom

NCT05014399

RECRUITING 40 participants

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Mclean Hospital

NCT05245903

RECRUITING 35 participants

The Better, Harder, Faster, Stronger Study

Wake Forest University Health Sciences

NCT07220512

RECRUITING 30 participants

Surviving Daily Life

Thomas Jefferson University

NCT07054723

RECRUITING NA 30 participants

Long COVID Brain Fog: Cognitive Rehabilitation Trial

University of Alabama at Birmingham

NCT06095297

RECRUITING NA 24 participants

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

Portland VA Medical Center

NCT06728774

RECRUITING NA 24 participants

A Pilot RCT to Improve Cognitive Processing Speed in Acute SCI

Kessler Foundation

NCT06238492

RECRUITING NA 20 participants

Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study

Kessler Foundation

NCT06452264

RECRUITING Phase 2 20 participants

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Michal Schnaider Beeri, Ph.D.

NCT07392723

RECRUITING Phase 1 12 participants

Stem Cell Therapy for Early Alzheimer's Disease

Paul E Schulz

NCT06775964

ACTIVE NOT RECRUITING NA 41,500 participants

ToolBox Detect: Low Cost Detection of Cognitive Decline in Primary Care Settings

Northwestern University

NCT04852601

ACTIVE NOT RECRUITING 13,435 participants

Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias

Anne Murray

NCT07224139

ACTIVE NOT RECRUITING 600 participants

BRINK (BRain In Kidney Disease) Memory Study 2.0

Anne Murray

NCT04975464

ACTIVE NOT RECRUITING Phase 2 523 participants

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

Janssen Research & Development

NCT04619420

ACTIVE NOT RECRUITING NA 253 participants

Improving Cognition After Cancer

University of California, San Diego

NCT04049695

ACTIVE NOT RECRUITING 210 participants

Recurrence Markers, Cognitive Burden and Neurobiological Homeostasis in Late-Life Depression

University of Illinois at Chicago

NCT05331599

ACTIVE NOT RECRUITING 194 participants

Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia

University of Texas Southwestern Medical Center

NCT04951700

ACTIVE NOT RECRUITING NA 82 participants

Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke

University of Alabama at Birmingham

NCT05162781

ACTIVE NOT RECRUITING Phase 2 12 participants

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

New York State Psychiatric Institute

NCT05690503

ACTIVE NOT RECRUITING NA 11 participants

HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS)

Dartmouth-Hitchcock Medical Center

NCT06145737

ACTIVE NOT RECRUITING NA 10 participants

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

Dartmouth-Hitchcock Medical Center

NCT06391489

ACTIVE NOT RECRUITING NA 10 participants

HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)

Dartmouth-Hitchcock Medical Center

NCT06260228

COMPLETED 1,098 participants

Characteristics and Outcomes of a Capacity-to-Consent Assessment Service

National Institutes of Health Clinical Center (CC)

NCT03258606

COMPLETED Phase 2 603 participants

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Targacept

NCT01488929

COMPLETED Phase 3 276 participants

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

Wake Forest University Health Sciences

NCT02822573

COMPLETED NA 182 participants

A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research

University of Wisconsin, Madison

NCT05444244

COMPLETED NA 69 participants

Noninvasive Brain Stimulation for Mild Cognitive Impairment

Palo Alto Veterans Institute for Research

NCT03331796

COMPLETED Early Phase 1 34 participants

Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD

University of Colorado, Denver

NCT04600323

COMPLETED NA 30 participants

Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction

Icahn School of Medicine at Mount Sinai

NCT06739668

COMPLETED Early Phase 1 24 participants

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Carol Fabian, MD

NCT02517502

COMPLETED NA 24 participants

Brain Vascular and Neurocognitive Health

The University of Texas at Arlington

NCT06497413

COMPLETED NA 16 participants

Computer Cognitive Training for Post-acute COVID-19 Syndrome

Nova Southeastern University

NCT05338749

COMPLETED NA 15 participants

A Pilot Randomized Controlled Trial: CoINTEGRATE

University of Michigan

NCT05732285

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5
Phase 3 1

Named interventions

Most-linked intervention names on Cognitive Dysfunction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) Behavioral
2 trials
game-like computerized activities Behavioral
2 trials
none, observational study Other
2 trials
Sodium Bicarbonate Tablets Drug
1 trials
Placebo rTMS (Inactive) Device
1 trials
Active rTMS (Bilateral LPC) Device
1 trials
Active rTMS (Bilateral DLPFC) Device
1 trials

US sites by state

Facility locations filed on Cognitive Dysfunction trials. A trial with sites in several states counts in each.

California 8 trials
New Hampshire 5 trials
Florida 5 trials
Texas 4 trials
New Jersey 4 trials
Illinois 4 trials
Alabama 4 trials
New York 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cognitive Dysfunction page

46 registered trials, 23 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cognitive Dysfunction condition card totals 46 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.